221 related articles for article (PubMed ID: 29724201)
1. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
Zhang H; Rose BJ; Pyuen AA; Thamm DH
BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
[TBL] [Abstract][Full Text] [Related]
2. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T
PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
Landini I; Massai L; Cirri D; Gamberi T; Paoli P; Messori L; Mini E; Nobili S
J Inorg Biochem; 2020 Jul; 208():111079. PubMed ID: 32497830
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.
Liu JJ; Liu Q; Wei HL; Yi J; Zhao HS; Gao LP
Pharmazie; 2011 Jun; 66(6):440-4. PubMed ID: 21699084
[TBL] [Abstract][Full Text] [Related]
7. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.
Chen X; Shi X; Zhao C; Li X; Lan X; Liu S; Huang H; Liu N; Liao S; Zang D; Song W; Liu Q; Carter BZ; Dou QP; Wang X; Liu J
Oncotarget; 2014 Oct; 5(19):9118-32. PubMed ID: 25193854
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.
Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
Cell Death Dis; 2014 Apr; 5(4):e1191. PubMed ID: 24763048
[TBL] [Abstract][Full Text] [Related]
9. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species.
Hwang-Bo H; Jeong JW; Han MH; Park C; Hong SH; Kim GY; Moon SK; Cheong J; Kim WJ; Yoo YH; Choi YH
Gen Physiol Biophys; 2017 Apr; 36(2):117-128. PubMed ID: 28218611
[TBL] [Abstract][Full Text] [Related]
10. Morin enhances auranofin anticancer activity by up-regulation of DR4 and DR5 and modulation of Bcl-2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells.
Hwang-Bo H; Lee WS; Nagappan A; Kim HJ; Panchanathan R; Park C; Chang SH; Kim ND; Leem SH; Chang YC; Kwon TK; Cheong JH; Kim GS; Jung JM; Shin SC; Hong SC; Choi YH
Phytother Res; 2019 May; 33(5):1384-1393. PubMed ID: 30887612
[TBL] [Abstract][Full Text] [Related]
11. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
12. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
Kato I; Kasukabe T; Kumakura S
Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
[TBL] [Abstract][Full Text] [Related]
13. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma.
Van Loenhout J; Freire Boullosa L; Quatannens D; De Waele J; Merlin C; Lambrechts H; Lau HW; Hermans C; Lin A; Lardon F; Peeters M; Bogaerts A; Smits E; Deben C
Cells; 2021 Oct; 10(11):. PubMed ID: 34831159
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation.
Radenkovic F; Holland O; Vanderlelie JJ; Perkins AV
Biochem Pharmacol; 2017 Dec; 146():42-52. PubMed ID: 28947276
[TBL] [Abstract][Full Text] [Related]
16. Comparative oncology approach to drug repurposing in osteosarcoma.
Parrales A; McDonald P; Ottomeyer M; Roy A; Shoenen FJ; Broward M; Bruns T; Thamm DH; Weir SJ; Neville KA; Iwakuma T; Fulbright JM
PLoS One; 2018; 13(3):e0194224. PubMed ID: 29579058
[TBL] [Abstract][Full Text] [Related]
17. Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer.
Oh BM; Lee SJ; Cho HJ; Park YS; Kim JT; Yoon SR; Lee SC; Lim JS; Kim BY; Choe YK; Lee HG
Cell Death Dis; 2017 Mar; 8(3):e2682. PubMed ID: 28300829
[TBL] [Abstract][Full Text] [Related]
18. Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.
Schuh E; Pflüger C; Citta A; Folda A; Rigobello MP; Bindoli A; Casini A; Mohr F
J Med Chem; 2012 Jun; 55(11):5518-28. PubMed ID: 22621714
[TBL] [Abstract][Full Text] [Related]
19. Auranofin is a potent suppressor of osteosarcoma metastasis.
Topkas E; Cai N; Cumming A; Hazar-Rethinam M; Gannon OM; Burgess M; Saunders NA; Endo-Munoz L
Oncotarget; 2016 Jan; 7(1):831-44. PubMed ID: 26573231
[TBL] [Abstract][Full Text] [Related]
20. Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma.
Endo-Munoz L; Bennett TC; Topkas E; Wu SY; Thamm DH; Brockley L; Cooper M; Sommerville S; Thomson M; O'Connell K; Lane A; Bird G; Peaston A; Matigian N; Straw RC; Saunders NA
Vet Comp Oncol; 2020 Jun; 18(2):206-213. PubMed ID: 31441983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
